OertliKatalyst introduces vitreoretinal hand instruments

Article

Oertli has introduced OertliKatalyst, a new brand in conjunction with Katalyst.

Oertli has introduced OertliKatalyst, a new brand in conjunction with Katalyst.

OertliKatalyst consists of a new handpiece set, innovative tip geometrics, a choice of material and improved implementation of ergonomic basic principles. The brand has been developed from scratch and has resulted in numerous patent registrations.

Thomas Bosshard, Head of Marketing and Sales at Oertli, said, " We were looking for the right moment to launch and the right moment to bring the right combination of vitreo hand instruments. We looked at things like laser probes and forceps, scissors, polishers and so on. We wanted the right partner at the right moment and the right resources."

The retinal instruments were first launched at this year's ESCRS congress in Milan. CEO of Katalyst, Greg Scheller, commented, "They feature about 15 new tip designs that have not been previously available in the vitreoretinal market. We also have laser probes that have not yet been introduced in the world market. But they have in the US, as well as diamond membrane polishers. We will be introducing a continuous line of products as both companies move forward."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.